Ketoprofen Extended-Release Capsules and Piqray
Determining the interaction of Ketoprofen Extended-Release Capsules and Piqray and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9. MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered. References "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9.
MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered.
- "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: ketoprofen
Brand name: Oruvail, Orudis, Actron, Orudis KT
Synonyms: Ketoprofen
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ketoprofen Extended-Release Capsules-Piqray 200MG Daily Dose
- Ketoprofen Extended-Release Capsules-Piqray 250MG Daily Dose
- Ketoprofen Extended-Release Capsules-Piqray 300MG Daily Dose
- Ketoprofen Extended-Release Capsules-Pirbuterol Inhalation
- Ketoprofen Extended-Release Capsules-Pirfenidone
- Ketoprofen Extended-Release Capsules-Pirmella 1/35
- Piqray-Ketorolac
- Piqray-Ketorolac (Systemic)
- Piqray-Ketorolac Eye Drops (Multi-Dose Containers)
- Piqray-Ketorolac Eye Drops (Single-Dose Containers)
- Piqray-Ketorolac Injection
- Piqray-Ketorolac nasal